Literature DB >> 3066393

The multidrug resistance phenotype.

S B Kaye1.   

Abstract

Mesh：

Year:  1988        PMID： 3066393      PMCID： PMC2246872          DOI： 10.1038/bjc.1988.291

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  40 in total

1.  Possible link between the intrinsic drug resistance of colon tumors and a detoxification mechanism of intestinal cells.

Authors:  W D Klohs; R W Steinkampf
Journal:  Cancer Res       Date:  1988-06-01       Impact factor: 12.701

2.  A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants.

Authors:  R L Juliano; V Ling
Journal:  Biochim Biophys Acta       Date:  1976-11-11

3.  Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies.

Authors:  J L Biedler; H Riehm
Journal:  Cancer Res       Date:  1970-04       Impact factor: 12.701

4.  Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers.

Authors:  T Tsuruo; H Iida; M Nojiri; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1983-06       Impact factor: 12.701

5.  In vivo resistance towards anthracyclines, etoposide, and cis-diamminedichloroplatinum(II).

Authors:  S Seeber; R Osieka; C G Schmidt; W Achterrath; S T Crooke
Journal:  Cancer Res       Date:  1982-11       Impact factor: 12.701

6.  Promotion by verapamil of vincristine responsiveness in tumor cell lines inherently resistant to the drug.

Authors:  T Tsuruo; H Iida; K Naganuma; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1983-02       Impact factor: 12.701

7.  Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines.

Authors:  N Kartner; J R Riordan; V Ling
Journal:  Science       Date:  1983-09-23       Impact factor: 47.728

8.  Potentiation of doxorubicin cytotoxicity by the calcium antagonist bepridil in anthracycline-resistant and -sensitive cell lines. A comparison with verapamil.

Authors:  G J Schuurhuis; H J Broxterman; J J van der Hoeven; H M Pinedo; J Lankelma
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

9.  Potentiation of vincristine and Adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors.

Authors:  T Tsuruo; H Iida; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1983-05       Impact factor: 12.701

10.  Increased plasma membrane traffic in daunorubicin resistant P388 leukaemic cells. Effect of daunorubicin and verapamil.

Authors:  M Sehested; T Skovsgaard; B van Deurs; H Winther-Nielsen
Journal:  Br J Cancer       Date:  1987-12       Impact factor: 7.640
View more
  28 in total

1.  Establishment of two new multi-drug resistant variants of the human tumor line Hep-2.

Authors:  A Redmond; E Law; U Gilvarry; M Clynes
Journal:  Cell Biol Toxicol       Date:  1990-07       Impact factor: 6.691

Review 2.  Causes and problems of nonresponse or poor response to drugs.

Authors:  P Salvà Lacombe; J A García Vicente; J Costa Pagès; P Lucio Morselli
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

3.  Current status and future directions of research on multidrug resistance. The impact of contemporary biotechnology.

Authors:  G H Mickisch
Journal:  Urol Res       Date:  1993-03

4.  Histopathological assessment of multidrug resistance in gastric cancer: expression of P-glycoprotein, multidrug resistance-associated protein, and lung-resistance protein.

Authors:  D Alexander; T Yamamoto; S Kato; S Kasai
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

5.  How curable is relapsed Wilms' tumour? The United Kingdom Children's Cancer Study Group.

Authors:  J J Groot-Loonen; C R Pinkerton; P H Morris-Jones; J Pritchard
Journal:  Arch Dis Child       Date:  1990-09       Impact factor: 3.791

6.  Modulation of doxorubicin-toxicity by tamoxifen in multidrug-resistant tumor cells in vitro and in vivo.

Authors:  E Pommerenke; J Mattern; M Volm
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

7.  Flow cytometric analysis of multidrug-resistance-associated antigen (P-glycoprotein) and DNA ploidy in human colon cancer.

Authors:  M Danova; M Giordano; E Erba; S Palmeri; V Candiloro; A Riccardi; G Ucci; G Mazzini; M D'Incalci; E Ascari
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

8.  Effects of various methoxyflavones on vincristine uptake and multidrug resistance to vincristine in P-gp-overexpressing K562/ADM cells.

Authors:  Hisakazu Ohtani; Tomomi Ikegawa; Youko Honda; Noriko Kohyama; Satoshi Morimoto; Yukihiro Shoyama; Motoharu Juichi; Mikihiko Naito; Takashi Tsuruo; Yasufumi Sawada
Journal:  Pharm Res       Date:  2007-05-10       Impact factor: 4.200

9.  Enhancement of cisplatin (DDP) antitumor activity by 3-aminobenzamide in rat ovarian tumors sensitive and resistant to DDP in vivo.

Authors:  G Chen; W J Zeller
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

10.  Growth-inhibitory properties of novel anthracyclines in human leukemic cell lines expressing either Pgp-MDR or at-MDR.

Authors:  M Mariani; L Capolongo; A Suarato; A Bargiotti; N Mongelli; M Grandi; W T Beck
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.